1OHR

VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Work: 0.200 
  • R-Value Observed: 0.200 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Kaldor, S.W.Kalish, V.J.Davies 2nd., J.F.Shetty, B.V.Fritz, J.E.Appelt, K.Burgess, J.A.Campanale, K.M.Chirgadze, N.Y.Clawson, D.K.Dressman, B.A.Hatch, S.D.Khalil, D.A.Kosa, M.B.Lubbehusen, P.P.Muesing, M.A.Patick, A.K.Reich, S.H.Su, K.S.Tatlock, J.H.

(1997) J Med Chem 40: 3979-3985

  • DOI: 10.1021/jm9704098
  • Primary Citation of Related Structures:  
    1OHR

  • PubMed Abstract: 
  • Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor (Ki = 2 nM) and antiviral agent (HIV-1 ED50 = 14 nM) ...

    Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor (Ki = 2 nM) and antiviral agent (HIV-1 ED50 = 14 nM). An X-ray cocrystal structure of the enzyme-AG1343 complex reveals how the novel thiophenyl ether and phenol-amide substituents of the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively. In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. AG1343 (Viracept) has recently been approved for marketing for the treatment of AIDS.


    Organizational Affiliation

    Agouron Pharmaceuticals, Inc., San Diego, California 92121, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
ASPARTYLPROTEASEAB99Human immunodeficiency virus 1Mutation(s): 0 
Gene Names: v-1 PROTEASE
Find proteins for Q9Q288 (Human immunodeficiency virus 1)
Explore Q9Q288 
Go to UniProtKB:  Q9Q288
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
1UN
Query on 1UN

Download CCD File 
A
2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE
C32 H45 N3 O4 S
QAGYKUNXZHXKMR-HKWSIXNMSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
1UNIC50:  1.899999976158142   nM  BindingDB
1UNKd:  38   nM  BindingDB
1UNKi :  2   nM  PDBBind
1UNIC50:  530   nM  BindingDB
1UNKi:  0.07000000029802322   nM  BindingDB
1UNIC50:  9   nM  BindingDB
1UNKd:  3.4000000953674316   nM  BindingDB
1UNKi:  2   nM  BindingDB
1UNKd:  3   nM  BindingDB
1UNKi:  2   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Work: 0.200 
  • R-Value Observed: 0.200 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 52.04α = 90
b = 59.38β = 90
c = 61.67γ = 90
Software Package:
Software NamePurpose
X-PLORmodel building
X-PLORrefinement
X-PLORphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 1997-09-27 
  • Released Date: 1998-12-09 
  • Deposition Author(s): Davies II, J.F.

Revision History 

  • Version 1.0: 1998-12-09
    Type: Initial release
  • Version 1.1: 2008-03-03
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance